Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease.

Naunyn Schmiedebergs Arch Pharmacol · 2021 · PMC8298375 · PMID 34086100

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Meanwhile, all rivastigmine-treated groups exhibited significantly shortened escape latency times, but the extent of reduction was highly significant in INRL group compared to the scopolamine-alone-treated group.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.